Medicus Pharma gains independent validation for SkinJect Phase 2 data

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company’s Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao’s independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma’s continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a rigorous framework to isolate the incremental benefit of the drug component while also assessing both visual (clinical) and histological clearance endpoints. Dr. Rao emphasized that the trial design enables a clear understanding of treatment effectiveness, combining real-world clinical observations with detailed pathological analysis. He noted that the findings carry important implications for patient care, particularly in reducing reliance on invasive procedures. One of the most compelling outcomes highlighted was that approximately three out of four treated lesions achieved visual tumor clearance. This suggests that a significant number of patients could potentially avoid immediate surgical intervention, offering a less invasive treatment alternative for certain forms of skin cancer. Dr. Rao, a dermatologist, dermatopathologist, Mohs surgeon, and clinical investigator, brings extensive expertise in skin oncology. He serves as Professor of Dermatology and Pathology and Director of Clinical Research at Rutgers Robert Wood Johnson Medical School, with additional academic roles at Weill Cornell Medical College and California Health Sciences University. The independent validation strengthens Medicus Pharma’s position as it continues to develop SkinJect as a novel, minimally invasive treatment option, with the potential to reshape how certain skin cancers are managed in clinical practice #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Dermatology #SkinCancer #BasalCellCarcinoma #OncologyInnovation #Biotech #DrugDelivery #Microneedle #Doxorubicin #ClinicalResearch #HealthcareInnovation #MedicalBreakthrough #ProactiveInvestors